CATALYST PHARMS
SpecialtyCATALYST PHARMS is a specialty pharmaceutical company focused on Neurology. Key products include FYCOMPA.
FDA Novel Drug Designations
(2018-2023)CATALYST PHARMS at a Glance
- Fast trial execution (23 months median completion)
CATALYST PHARMS's Key Drugs
CATALYST PHARMS's core commercial portfolio centers on FYCOMPA, AGAMREE, FIRDAPSE, spanning Neurology — its most strategically important drugs approved in the last 15 years.
CATALYST PHARMS's Recent FDA Approvals
New NDA/BLA approvals for CATALYST PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
CATALYST PHARMS's Therapeutic Areas
CATALYST PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CATALYST PHARMS's Top Competitors
CATALYST PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CATALYST PHARMS Pipeline Snapshot
Active clinical trials for CATALYST PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • FYCOMPA leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 4/5 completed
- • Speed: 23 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges